Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
RexaCur AB
AB
Active
Org 5594262817
Datavägen 12 A, 436 32
Askim
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2023 · 3 years old
1 employees
Monitor
Share
Sweden
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
RexaCur AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
55M
41M
27M
14M
0M
2023: 4M
4M
2023
2024: 30M (+650% vs 2023)
30M
+650%
2024
2025: 44M (+47% vs 2024)
44M
+47%
2025
EBITDA
SEK millions
1M
1M
1M
0M
0M
2023: 0M
0M
2023
2024: 1M
1M
2024
2025: 1M (0% vs 2024)
1M
0%
2025
Income statement
SEK thousands
Item
2025
2024
2023
Revenue
44 119
30 468
3 815
Staff expenses
−948
−12
−8
EBITDA
614
1 252
21
Depreciation & amort.
—
—
—
EBIT
614
1 252
21
Net financials
−48
−80
−13
Profit before tax
419
880
8
Tax
−91
−181
−2
Net profit
328
698
6
Balance sheet
SEK thousands
Item
2025
2024
2023
Total assets
33 457
11 472
4 113
Equity
1 057
730
31
Long-term debt
213
425
622
Short-term debt
31 748
10 025
3 460
Total debt
31 961
10 450
4 082
Financial ratios
5-year trend
EBITDA margin
1,4 %
This company
15,8 %
Market median
This company
Market median
91% below market
2023
2025
Equity ratio
3,2 %
This company
38,2 %
Market median
This company
Market median
92% below market
2023
2025
Return on equity
31,0 %
This company
18,4 %
Market median
This company
Market median
68% above market
2023
2025
Net profit margin
0,7 %
This company
8,1 %
Market median
This company
Market median
91% below market
2023
2025
Asset turnover
1,32×
This company
1,12×
Market median
This company
Market median
18% above market
2023
2025
Debt / equity
30,64×
This company
0,62×
Market median
This company
Market median
>999% above market
2023
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-03-15 – 2023-12-31
View
PDF
More on RexaCur AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
